Navigation Links
Synthetic Biologics Reports First Quarter 2013 Financial Results
Date:5/15/2013

ROCKVILLE, Md., May 15, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three months ended March 31, 2013 and summarized operational highlights.

Operational HighlightsEmphasis on C. difficile (C. diff) Infection Prevention (SYN-004)

  • In the U.S. each year, 24 million patients are administered IV antibiotics[1] which may be excreted into the gastrointestinal (GI) tract where they can upset the natural balance of the microbiome allowing for the overgrowth of C. difficile which causes diarrhea, colitis and may result in death.
  • SYN-004 is being developed as an oral enzyme product to be co-administered with IV beta-lactam antibiotics. SYN-004 is expected to:
  • Remain in the GI tract to degrade certain beta-lactam antibiotics
  • Protect the healthy microflora from the overgrowth of C. diff
  • In 2012, over 13 million patients were treated with IV beta-lactam antibiotics that may be covered by SYN-004.[1]
  • Phase I and II studies of over 200 subjects treated with 1st generation candidate demonstrated safety, tolerability, and preservation of the normal GI microflora when co-administered with certain penicillins.
  • Infectious Disease Specialist Joins Scientific Advisory Board

  • Brad Spellberg , M.D., is an Associate Professor of Medicine, David Geffen School of Medicine in the Division of General Internal Medicine at Harbor-UCLA Medical Center, and Associate Program Director for Internal Medicine Residency Training Program, Harbor-UCLA Medical Center and LA BioMed.
  • Dr. Spellberg has worked closely with the Infectious Diseases Society of America (IDSA) to focus attention on the rising public health
    '/>"/>

  • SOURCE Synthetic Biologics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Peripheral Vascular Devices Market (Peripheral Vascular Stents, PTA Balloon Catheters, Guidewires, IVC Filters, Atherectomy, Chronic Total Occlusion, Embolic Protection Devices, Synthetic Surgical Grafts, Aortic Stents) - Global Industry Analysis, S
    2. Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at BIO International Convention in Chicago, April 22-25
    3. Synthetic Biologics Reports Year End 2012 Financial Results
    4. What Will Thermo Fisher Scientific and Life Technologies $14 billion Merger hold for the Top Ten Suppliers of Synthetic Biology Technology and DNA Sequencing Landscape?
    5. Synthetic Biologics to Present at the 25th Annual ROTH Conference
    6. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
    7. Inovios Synthetic Flu Vaccine Doubles Rate of Elderly Subjects Displaying Protective Immune Responses
    8. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
    9. Inovio Expands Synthetic Vaccine Intellectual Property License With University of Pennsylvania
    10. The Use of New Replikins Synthetic Vaccines to Prevent Pandemics to be Presented at Influenza Congress Nov. 12 in Washington DC
    11. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... CHAPEL HILL, N.C. , Aug. 28, 2015 ... critical market research projects can slow down the ... costs. It is, therefore, absolutely critical for biopharmaceutical ... the market research approval process for quicker and ... recent research by Best Practices, LLC, nearly three-quarters ...
    (Date:8/28/2015)... 2015 Research and ... of the "Investigation Report on China,s Pranoprofen ... Originally discovered by Welfide (Mitsubishi Tanabe Pharma ... as an inflammatory drug, pranoprofen was later developed ... under the trade name of pranopulin for the ...
    (Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Tobramycin Market, 2010-2019" ... traditional antibiotic whose eye drop and ointment are the ... infection or inflammation caused by eye infection. Currently, dozens ... able to produce tobramycin, among which the Top 5 ...
    Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
    ... 2010 Genomic Health, Inc. (Nasdaq: GHDX ) today ... 30, 2010. Total revenue increased to $46.3 million in ... third quarter of 2009.  Product revenue was $45.8 million in the ... $38.9 million in the third quarter of 2009. ...
    ... Nov. 8, 2010 PRNewswire-FirstCall/ -- Mesa Laboratories, Inc. (Nasdaq: ... has declared a regular quarterly dividend of $.12 per share ...  The dividend will be payable December 15, 2010, to shareholders ... public in 1984 Mesa Labs has maintained strong cash positions ...
    Cached Medicine Technology:Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 2Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 3Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 4Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 5Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 6Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 7Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 8
    (Date:8/29/2015)... ... August 29, 2015 , ... "I ... from Miller Place, N.Y. "I specialize in manual therapy, and my invention will ... can be used for additional muscle dysfunction throughout the body." , They developed ...
    (Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... mesothelioma develops, may extend and improve the lives of patients, according to a ... Click here to read the full article. , The authors of ...
    (Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik ... zero standard shipping costs. , “Before, a threshold of $49.00 was required to qualify ... and items qualify for free standard shipping for customers regardless of the item’s selling ...
    (Date:8/29/2015)... ... , ... ProDrop Particles includes over 40 particle backdrops designed for use in ... that users can shrink and stretch in the Final Cut Pro X timeline. Choose ... brightness, scale, speed, range, and flare attributes with intuitive controls found in the top-right ...
    (Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 ... ... successful results and include treating the localized area with stretching, soft tissue manipulation. ... a neutral pelvic position have shown through research to improve treatment outcomes. ...
    Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
    ... the Ganesh Shanker Vidyarthi Memorial (GSVM) Medical College have ... // in bringing medical knowledge and technology that would ... ,The two institutes have signed a memorandum ... increased collaboration on several fronts. ,The heads ...
    ... Association (AMA) says that the federal budget has poorly ... for not addressing problems like obesity //and indigenous health. ... develop world-first medical technologies to fight cancer and heart ... for the National Health and Medical Research Council by ...
    ... Japanese Encephalitis immunisation which was initially scheduled to take ... 15. //The Uttar Pradesh government is responsible for the ... dates. Japanese Encephalitis is the main reason for the ... Statistics show that in UP alone about 600-700 children ...
    ... of fungal infection in Bausch and Lomb lens wearers are ... association arrived at is that nearly 50% of those who ... solution, manufactured by Bausch and Lomb. ,Bausch & ... solution, feels that the cause of Fusarium keratitis infection is ...
    ... study, drinking tap water increases the risk of bladder cancer. ... if one drink too much of it may be a ... published in the April 15 issue of International Journal of ... based drinks each day increased the risk of bladder cancer ...
    ... Research (ICAR) has identified Indira Kankoda I (RMF 37), ... Chhattisgarh, Uttar Pradesh, Jharkhand, Orissa and Maharashtra. ... will be the first spine gourd variety identified for ... vegetable crop locally known as Meetha Karela, Khekhsa, Padora ...
    Cached Medicine News:
    ... Lyphochek Fertility Control ... monitor the clinically significant ... most frequently assayed during ... Elevated hCG and hCG-Beta ...
    Liquichek Spinal Fluid Control is a liquid, bilevel product designed to monitor the performance of automated and manual procedures for the analysis of proteins and other critical analytes assayed in ...
    The Acceava hCG Combo test provides superior performance for the diagnosis of pregnancy with a simple procedure that provides easy to read black on white results in 3 minutes for urine or 5 minutes f...
    ... Nucleic Sample Preparation Platform provides flexible, automated ... platform can prepare up to 96 patient ... and one half-hours, and performs onboard quantitation ... 30 minutes each. Based on Beckman ...
    Medicine Products: